Jesus G. Berdeja, MD

Jesus G. Berdeja, MD, discusses the potential of chimeric antigen receptor T-cell therapy to be approved for earlier lines of treatment in multiple myeloma.

Jesus G. Berdeja, MD, director of multiple myeloma research at Sarah Cannon Research Institute and hematology specialist at Tennessee Oncology, discusses the results of the CARTITUDE-1 trial for chimeric antigen receptor T-cell therapy with the newly-approved agent ciltacabtagene autoleucel for relapsed/refractory multiple myeloma.

Jesus G. Berdeja, MD, discusses the findings from the phase 2 results of ciltacabtagene autoleucel as treatment of patients with relapsed/refractory multiple myeloma in the CARTITUDE-1 study.

Jesus G. Berdeja, MD, director of Myeloma Research, senior investigator, Hematologic Malignancies Principal Investigator, Sarah Cannon Research Institute, discusses a phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed or relapsed/refractory multiple myeloma.